I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?
- PMID: 27406345
- DOI: 10.1056/NEJMp1602256
I-SPY 2--A Glimpse of the Future of Phase 2 Drug Development?
Comment in
-
Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med. 2016 Oct 20;375(16):1592-3. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 27797314 No abstract available.
-
Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med. 2016 Oct 20;375(16):1591-2. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 27797315 No abstract available.
-
Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med. 2016 Oct 20;375(16):1592. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 28103001 No abstract available.
-
Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med. 2016 Oct 20;375(16):1593-4. doi: 10.1056/NEJMc1609993. N Engl J Med. 2016. PMID: 28103002 No abstract available.
Comment on
-
Adaptive Randomization of Neratinib in Early Breast Cancer.N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750. N Engl J Med. 2016. PMID: 27406346 Free PMC article. Clinical Trial.
-
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749. N Engl J Med. 2016. PMID: 27406347 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources